Therapeutic Applications

Adverse Effects of Engineered Nanomaterials

Volumn , Issue , 2012, Pages 285-313

  Bussy, Cyrill ^a   Alexiou, Christoph ^b   Petros, Robby A ^c   Nyström, Andreas M ^d   Methven, Laura ^a   Kostarelos, Kostas ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b Section for Experimental Oncology and Nanomedicine   (Germany)

^c UNIVERSITY OF NORTH TEXAS   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84876489512     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-386940-1.00016-7     Document Type: Chapter

References (141)

1. Wagner V., Dullaart A., Bock A.K., Zweck A. The emerging nanomedicine landscape. Nat Biotechnol 2006, 24:1211-1217.
2. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
3. Perkins W.R., Ahmad I., Li X.G., et al. Novel therapeutic nano-particles (lipocores): Trapping poorly water soluble compounds. Int J Pharmaceut 2000, 200:27-39.
4. Pankhurst Q.A., Thanh N.K.T., Jones S.K., Dobson J. Progress in applications of magnetic nanoparticles in biomedicine. J Phys D Appl Phys 2009, 42:224001.
5. Pankhurst Q.A., Connolly J., Jones S.K., Dobson J. Applications of magnetic nanoparticles in biomedicine. J Phys D Appl Phys 2003, 36:R167-R181.
6. Arap W., Haedicke W., Bernasconi M., et al. Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci USA 2002, 99:1527-1531.
7. Torchilin V.P. Drug targeting. Eur J Pharm Sci 2000, 11:S81-S91.
8. Gerlowski L.E., Jain R.K. Microvascular permeability of normal and neoplastic tissues. Microvasc Res 1986, 31:288-299.
9. Shen Z., Wei W., Zhao Y.J., et al. Thermosensitive polymer-conjugated albumin nanospheres as thermal targeting anti-cancer drug carrier. Eur J Pharm Sci 2008, 35:271-282.
10. Chuang C.Y., Don T.M., Chiu W.Y. Synthesis of chitosan-based thermo- and pH-responsive porous nanoparticles by temperature-dependent self-assembly method and their application in drug release. J Polymer Sci a Polymer Chem 2009, 47:5126-5136.
11. Shen Z.Y., Ma G.H., Dobashi T., Maki Y., Su Z.G. Preparation and characterization of thermo-responsive albumin nanospheres. Int J Pharm 2008, 346:133-142.
12. Lee C.F., Wen C.J., Lin C.L., Chiu W.Y. Morphology and temperature responsiveness-swelling relationship of poly(N-isopropylamide-chitosan) copolymers and their application to drug release. J Polymer Sci a Polymer Chem 2004, 42:3029-3037.
13. Chuang C.Y., Don T.M., Chiu W.Y. Synthesis and properties of chitosan-based thermo- and pH-responsive nanoparticles and application in drug release. J Polymer Sci a Polymer Chem 2009, 47:2798-2810.
14. Stover T.C., Kim Y.S., Lowe T.L., Kester M. Thermoresponsive and biodegradable linear-dendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug. Biomaterials 2008, 29:359-369.
15. Bakhtiari A.B.S., Hsiao D., Jin G.X., Gates B.D., Branda N.R. An efficient method based on the photothermal effect for the release of molecules from metal nanoparticle surfaces. Angewandte Chem Int Ed 2009, 48:4166-4169.
16. Bilkenroth U., Taubert H., Riemann D., Rebmann U., Heynemann H., Meye A. Detection and enrichment of disseminated renal carcinoma cells from peripheral blood by immunomagnetic cell separation. Int J Cancer 2001, 92:577-582.
17. Taupitz M., Wagner S., Hamm B., Dienemann D., Lawaczeck R., Wolf K.J. MR lymphography using iron oxide particles. Detection of lymph node metastases in the VX2 rabbit tumour model. Acta Radiol 1993, 34:10-15.
18. Harisinghani M.G., Barentsz J., Hahn P.F., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003, 348:2491-2499.
19. Gao Y. Biofunctionalization of nanomaterials 2005, Wiley-VCH Verlag GmbH & Co. KGaA. K.C.S. Weinheim (Ed.).
20. Storm G., Belliot S.O., Daemen T., Lasic D.D. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliver Rev 1995, 17:31-48.
21. Muller R.H., Jacobs C., Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001, 47:3-19.
22. Alksne J.F., Fingerhut A., Rand R. Magnetically controlled metallic thrombosis of intracranial aneurysms. Surgery 1966, 60:212-218.
23. Widder K.J., Morris R.M., Howard D.P., Poore G.A., Senyei A.E. Selective targeting of magnetic albumin microspheres to the yoshida sarcoma: Ultrastructural evalutation of microsphere distribution. Eur J Cancer Clin Oncol 1993, 19:141-147.
24. Wilson M.W., Kerlan R.K., Fidelman N.A., et al. Hepatocellular carcinoma: Regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/conventional angiography suite-initial experience with four patients. Radiology 2004, 230:287-293.
25. Lübbe A.S., Bergemann C., Riess H., et al. Clinical experiences with magnetic drag targeting: A phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res 1996, 5:4686-4693.
26. Alexiou C., Jurgons R., Schmid R.J., et al. Magnetic drug targeting-biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J Drug Target 2003, 11:139-149.
27. Alexiou C., Diehl D., Henninger P., et al. A high field gradient magnet for magnetic drug targeting. IEEE Transact Appl Superconduct 2006, 16:1527-1530.
28. Brigger I., Morizet J., Laudani L., et al. Negative preclinical results with stealth((R)) nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model. J Contr Release 2004, 100:29-40.
29. Alexiou C., Jurgons R., Schmid R., et al. Magnetic drug targeting-a new approach in locoregional tumortherapy with chemotherapeutic agents. Experimental animal studies. Hno 2005, 53:618-622.
30. Alexiou C., Arnold W., Hulin P., et al. Magnetic mitoxantrone nanoparticle detection by histology, X-ray and MRI after magnetic tumor targeting. J Magn Magn Mater 2001, 225:187-193.
31. Rahn H., Gomez-Morilla I., Jurgons R., Alexiou C., Odenbach S. Microcomputed tomography analysis of ferrofluids used for cancer treatment. J Phys-Condensed Matt 2008, 20:204152-204156.
32. Tietze R., Rahn H., Lyer S., et al. Visualization of superparamagnetic nanoparticles in vascular tissue using X mu CT and histology. Histochem Cell Biol 2011, 135:153-158.
33. Alexiou Ch., Hulin P., Klein R.J., Bergemann Ch, Arnold W. Magnetic drug targeting: Biodistribution and dependency on magnetic field strength. J Magn Magn Mater 2002, 252:363-366.
34. Alexiou C., Arnold W., Klein R.J., et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res 2000, 60:6641-6648.
35. Alexiou C., Schmid R.J., Jurgons R., et al. Targeting cancer cells: Magnetic nanoparticles as drug carriers. Eur Biophys J Biophys Lett 2006, 35:446-450.
36. Levy-Nissenbaum E., Radovic-Moreno A.F., Wang A.Z., Langer R., Farokhzad O.C. Nanotechnology and aptamers: Applications in drug delivery. Trends Biotechnol 2008, 26:442-449.
37. Purushotham S., Chang P.E., Rumpel H., et al. Thermoresponsive core-shell magnetic nanoparticles for combined modalities of cancer therapy. Nanotechnology 2009, 20:305101-305112.
38. Welch M.J., Hawker C.J., Wooley K.L. The advantages of nanoparticles for PET. J Nucl Med 2009, 50:1743-1746.
39. Alexiou C., Tietze R., Schreiber E., Lyer S. Pharmakotherapie mittels nanomedizin-magnetische nanopartikel für drug delivery und hyperthermie-neue chancen für die krebstherapie. Bundesgesundheitsbl Gesundheitsforsch Gesundheitssch 2010, 53:839-845.
40. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9:615-627.
41. Davis M.E., Chen Z., Shin D.M. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
42. Zhang L., Gu F.X., Chan J.M., Wang A.Z., Langer R.S., Farokhzad O.C. Nanoparticles in medicine: Therapeutic applications and developments. Clin Pharmacol Ther 2008, 83:761-769.
43. Shi J., Votruba A.R., Farokhzad O.C., Langer R. Nanotechnology in drug delivery and tissue engineering: From discovery to applications. Nano Lett 2010, 10:3223-3230.
44. Geng Y., Dalhaimer P., Cai S.S., et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol 2007, 2:249-255.
45. Merkel T.J., Jones S.W., Herlihy K.P., et al. Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc Natl Acad Sci USA 2011, 108:586-591.
46. Dobrovolskaia M.A., Mcneil S.E. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007, 2:469-478.
47. Kohane D.S., Langer R. Biocompatibility and drug delivery systems. Chem Sci 2010, 1:441-446.
48. Parrott M.C., Luft J.C., Byrne J.D., Fain J.H., Napier M.E., DeSimone J. Tunable bifunctional silyl ether cross-linkers for the design of acid-sensitive biomaterials. J Am Chem Soc 2010, 132:17928-17932.
49. Maeda H., Greish K., Fang J. The EPR effect and polymeric drugs: A paradigm shift for cancer chemotherapy in the 21st century. Polymer Ther Ii: Polymers Drug Conjug Gene Deliv Sys 2006, 193:103-121.
50. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer-chemotherapy-mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs. Cancer Res 1986, 46:6387-6392.
51. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002, 2:750-763.
52. Byrne J.D., Betancourt T., Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008, 60:1615-1626.
53. Low P.S., Henne W.A., Doorneweerd D.D. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 2008, 41:120-129.
54. Gabizon A., Shmeeda H., Horowitz A.T., Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev 2004, 56:1177-1192.
55. Daniels T.R., Delgado T., Rodriguez J.A., Helguera G., Penichet M.L. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 2006, 121:144-158.
56. Daniels T.R., Delgado T., Helguera G., Penichet M.L. The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells. Clin Immunol 2006, 121:159-176.
57. Patri A.K., Myc A., Beals J., Thomas T.P., Bander N.H., Baker J.R. Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconj Chem 2004, 15:1174-1181.
58. Torchilin V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. Aaps J 2007, 9:E128-147.
59. Oh K.T., Yin H.Q., Lee E.S., Bae Y.H. Polymeric nanovehicles for anticancer drugs with triggering release mechanisms. J Mater Chem 2007, 17:3987-4001.
60. Ganta S., Devalapally H., Shahiwala A., Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release 2008, 126:187-204.
61. Petros R.A., Ropp P.A., DeSimone J.M. Reductively labile PRINT particles for the delivery of doxorubicin to HeLa cells. J Am Chem Soc 2008, 130:5008-5009.
62. Oh J.K., Siegwart D.J., Lee H.I., et al. Biodegradable nanogels prepared by atom transfer radical polymerization as potential drug delivery carriers: Synthesis, biodegradation, in vitro release, and bioconjugation. J Am Chem Soc 2007, 129:5939-5945.
63. Dhar S., Kolishetti N., Lippard S.J., Farokhzad O.C. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci USA 2011, 108:1850-1855.
64. Avgoustakis K., Beletsi A., Panagi Z., Klepetsanis P., Karydas A.G., Ithakissios D.S. PLGA-mPEG nanoparticles of cisplatin: In vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Contr Release 2002, 79:123-135.
65. Murphy E.A., Majeti B.K., Mukthavaram R., Acevedo L.M., Barnes L., Cheresh D.A. Targeted nanogels: A versatile platform for drug delivery to tumors. Mol Cancer Ther 2011, 10:972-982.
66. Harris A.N., Hinojosa B.M., Chavious M.D., Petros R.A. Beyond platinum: Synthesis, characterization, and in vitro toxicity of Cu(II)-releasing polymer nanoparticles for potential use as a drug delivery vector. Nanoscale Res Lett 2011, 6:445.
67. Jang W.D., Selim K.M.K., Lee C.H., Kang I.K. Bioinspired application of dendrimers: From bio-mimicry to biomedical applications. Prog Polymer Sci 2009, 34:1-23.
68. Nanjwade B.K., Bechra H.M., Derkar G.K., Manvi F.V., Nanjwade V.K. Dendrimers: Emerging polymers for drug-delivery systems. Eur J Pharm Sci 2009, 38:185-196.
69. Lee C.C., MacKay J.A., Frechet J.M.J., Szoka F.C. Designing dendrimers for biological applications. Nat Biotechnol 2005, 23:1517-1526.
70. D'Emanuele A., Attwood D. Dendrimer-drug interactions. Adv Drug Deliv Rev 2005, 57:2147-2162.
71. Hawker C.J., Wooley K.L., Frechet J.M.J. Unimolecular micelles and globular amphiphiles-dendritic macromolecules as novel recyclable solubilization agents. J Chem Soc Perkin Transact 1993, 1:1287-1297.
72. Moorefield C.N., Newkome G.R. Unimolecular micelles: Supramolecular use of dendritic constructs to create versatile molecular containers. Comptes Rend Chim 2003, 6:715-724.
73. Jansen J.F.G.A., Debrabandervandenberg E.M.M., Meijer E.W. Encapsulation of guest molecules into a dendritic box. Science 1994, 266:1226-1229.
74. Margerum L.D., Campion B.K., Koo M., et al. Gadolinium(III) DO3A macrocycles and polyethylene glycol coupled to dendrimers-effect of molecular weight on physical and biological properties of macromolecular magnetic resonance imaging contrast agents. J Alloys Compounds 1997, 249:185-190.
75. Roberts J.C., Bhalgat M.K., Zera R.T. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst(TM) dendrimers. J Biomed Mater Res 1996, 30:53-65.
76. Sarkar K., Yang H. Encapsulation and extended release of anti-cancer anastrozole by stealth nanoparticles. Drug Deliv 2008, 15:343-346.
77. Neerman M.F. The efficiency of a PAMAM dendrimer toward the encapsulation of the antileukernic drug 6-mercaptopurine. Anti-Cancer Drugs 2007, 18:839-842.
78. Bhadra D., Bhadra S., Jain S., Jain N.K. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm 2003, 257:111-124.
79. Kojima C., Kono K., Maruyama K., Takagishi T. Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconj Chem 2000, 11:910-917.
80. Cheng Y.Y., Li M.H., Xu T.W. Potential of poly(amidoamine) dendrimers as drug carriers of camptothecin based on encapsulation studies. Eur J Med Chem 2008, 43:1791-1795.
81. Morgan M.T., Carnahan M.A., Immoos C.E., et al. Dendritic molecular capsules for hydrophobic compounds. J Am Chem Soc 2003, 125:15485-15489.
82. Morgan M.T., Nakanishi Y., Kroll D.J., et al. Dendrimer-encapsulated camptothecins: Increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro. Cancer Res 2006, 66:11913-11921.
83. Malik N., Evagorou E.G., Duncan R. Dendrimer-platinate: A novel approach to cancer chemotherapy. Anti-Cancer Drugs 1999, 10:767-776.
84. Choi S.K., Thomas T., Li M.-H., Kotlyar A., Desai A., Baker J.R. Chem Commun 2010, 46:2632-2634.
85. Kono K., Kojima C., Hayashi N., et al. Biomaterials 2008, 29:1664-1675.
86. Zhu S.J., Hong M.H., Zhang L.H., Tang G.T., Jiang Y.Y., Pei Y.Y. Pharmaceut Res 2010, 27:161-174.
87. Majoros I.J., Myc A., Thomas T., Mehta C.B., Baker J.R. Biomacromolecules 2006, 7:572-579.
88. Saad M., Garbuzenko O.B., Ber E., et al. J Contr Release 2008, 130:107-114.
89. Khandare J.J., Jayant S., Singh A., et al. Bioconj Chem 2006, 17:1464-1472.
90. Zhao X.X., Loo S.C.J., Lee P.P.F., Tan T.T.Y., Chu C.K. J Inorgan Biochem 2010, 104:105-110.
91. Zhuo R.X., Du B., Lu Z.R. J Contr Release 1999, 57:249-257.
92. Patri A.K., Kukowska-Latallo J.F., Baker J.R. Adv Drug Deliv Rev 2005, 57:2203-2214.
93. Thomas T.P., Majoros I.J., Kotlyar A., et al. J Med Chem 2005, 48:3729-3735.
94. Kukowska-Latallo J.F., Candido K.A., Cao Z.Y., et al. Cancer Res 2005, 65:5317-5324.
95. Myc A., Kukowska-Latallo J., Cao P., et al. Anti-Cancer Drugs 2010, 21:186-192.
96. Majoros I.J., Thomas T.P., Mehta C.B., Baker J.R. J Med Chem 2005, 48:5892-5899.
97. Guillaudeu S.J., Fox M.E., Haidar Y.M., Dy E.E., Szoka F.C., Fréchet J.M.J. Bioconj Chem 2008, 19:461-469.
98. De Jesus O.L.P., Ihre H.R., Gagne L., Fréchet J.M.J., Szoka F.C. Polyester dendritic systems for drug delivery applications: In vitro and in vivo evaluation. Bioconj Chem 2002, 13:453-461.
99. Ihre H.R., De Jesus O.L.P., Szoka F.C., Fréchet J.M.J. Polyester dendritic systems for drug delivery applications: Design, synthesis, and characterization. Bioconj Chem 2002, 13:443-452.
100. Lee C.C., Gillies E.R., Fox M.E., et al. Proc Natl Acad Sci USA 2006, 103:16649-16654.
101. Lim J.D., Simanek E.E. Org Lett 2008, 10:201-204.
102. Lim J., Chouai A., Lo S.T., Liu W., Sun X.K., Simanek E.E. Bioconj Chem 2009, 20:2154-2161.
103. Venditto V.J., Allred K., Allred C.D., Simanek E.E. Intercepting the synthesis of triazine dendrimers with nucleophilic pharmacophores: A general strategy toward drug delivery vehicles. Chem Commun (Camb) 2009, 3:5541-5542.
104. Dumortier H., Lacotte S., Pastorin G., et al. Functionalized carbon nanotubes are non-cytotoxic and preserve the functionality of primary immune cells. Nano Lett 2006, 6:1522-1528.
105. Prato M., Kostarelos K., Bianco A. Functionalized carbon nanotubes in drug design and discovery. Acc Chem Res 2008, 41:60-68.
106. Liu Z., Tabakman S.M., Chen Z., Dai H.J. Preparation of carbon nanotube bioconjugates for biomedical applications. Nat Protocols 2009, 4:1372-1382.
107. Sayes C.M., Liang F., Hudson J.L., et al. Functionalization density dependence of single-walled carbon nanotubes cytotoxicity in vitro. Toxicol Lett 2006, 161:135-142.
108. Liu Z., Tabakman S., Welsher K., Dai H. Carbon nanotubes in biology and medicine: In vitro and in vivo detection, imaging and drug delivery. Nano Res 2009, 2:85-120.
109. Liu Z., Sun X., Nakayama-Ratchford N., Dai H. Supramolecular chemistry on water-soluble carbon nanotubes for drug loading and delivery. ACS Nano 2007, 1:50-56.
110. Liu Z., Fan A.C., Rakhra K., et al. Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy. Angew Chem Int Ed Engl 2009, 7668-7672.
111. Ali-Boucetta H., Al-Jamal K.T., McCarthy D., Prato M., Bianco A., Kostarelos K. Multiwalled carbon nanotube-doxorubicin supramolecular complexes for cancer therapeutics. Chem Commun (Camb.) 2008, 4:459-461.
112. Georgakilas V., Tagmatarchis N., Pantarotto D., Bianco A., Briand J.P., Prato M. Amino acid functionalisation of water soluble carbon nanotubes. Chem Commun (Camb.) 2002, 24:3050-3051.
113. Pantarotto D., Briand J.P., Prato M., Bianco A. Translocation of bioactive peptides across cell membranes by carbon nanotubes. Chem Commun (Camb.) 2004, 16-17.
114. Samori C., Ali-Boucetta H., Sainz R., et al. Enhanced anticancer activity of multi-walled carbon nanotube-methotrexate conjugates using cleavable linkers. Chem Commun (Camb.) 2010, 46:1494-1496.
115. Liu Z., Chen K., Davis C., et al. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res 2008, 68:6652-6660.
116. Bhirde A.A., Patel S., Sousa A.A., et al. Distribution and clearance of PEG-single-walled carbon nanotube cancer drug delivery vehicles in mice. Nanomedicine (Lond.) 2010, 5:1535-1546.
117. Meng J., Duan J., Kong H., et al. Carbon nanotubes conjugated to tumor lysate protein enhance the efficacy of an antitumor immunotherapy. Small 2008, 4:1364-1370.
118. Singh R., Pantarotto D., McCarthy D., et al. Binding and condensation of plasmid DNA onto functionalized carbon nanotubes: Toward the construction of nanotube-based gene delivery vectors. J Am Chem Soc 2005, 127:4388-4396.
119. Podesta J.E., Al-Jamal K.T., Herrero M.A., et al. Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model. Small 2009, 5:1176-1185.
120. Pantarotto D., Partidos C.D., Graff R., et al. Synthesis, structural characterization, and immunological properties of carbon nanotubes functionalized with peptides. J Am Chem Soc 2003, 125:6160-6164.
121. Pantarotto D., Partidos C.D., Hoebeke J., et al. Immunization with peptide-functionalized carbon nanotubes enhances virus-specific neutralizing antibody responses. Chem Biol 2003, 10:961-966.
122. Yang R., Yang X., Zhang Z., et al. Single-walled carbon nanotubes-mediated in vivo and in vitro delivery of siRNA into antigen-presenting cells. Gene Ther 2006, 13:1714-1723.
123. Kam N.W., O'Connell M., Wisdom J.A., Dai H. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc Natl Acad Sci USA 2005, 102:11600-11605.
124. Lee H.J., Park J., Yoon O.J., et al. Amine-modified single-walled carbon nanotubes protect neurons from injury in a rat stroke model. Nat Nanotechnol 2011, 6:121-125.
125. Al-Jamal K.T., et al. Functional motor recovery from brain ischemic insult by carbon nanotube-mediated siRNA silencing. Proc Natl Acad Sci USA 2011, 108:10952-10957.
126. Nayak T.R., Jian L., Phua L.C., Ho H.K., Ren Y., Pastorin G. Thin films of functionalized multiwalled carbon nanotubes as suitable scaffold materials for stem cells proliferation and bone formation. ACS Nano 2010, 4:7717-7725.
127. Chao T.I., Xiang S., Lipstate J.F., Wang C., Lu J. Poly(methacrylic acid)-grafted carbon nanotube scaffolds enhance differentiation of hESCs into neuronal cells. Adv Mater 2010, 22:3542-3547.
128. Tosun Z., McFetridge P.S. A composite SWNT-collagen matrix: characterization and preliminary assessment as a conductive peripheral nerve regeneration matrix. J Neural Eng 2010, 7. 066002.
129. Usui Y., Aoki K., Narita N., et al. Carbon nanotubes with high bone-tissue compatibility and bone-formation acceleration effects. Small 2008, 4:240-246.
130. Khang D., Sato M., Price R.L., Ribbe A.E., Webster T.J. Selective adhesion and mineral deposition by osteoblasts on carbon nanofiber patterns. Int J Nanomed 2006, 1:65-72.
131. Khang D., Park G.E., Webster T.J. Enhanced chondrocyte densities on carbon nanotube composites: The combined role of nanosurface roughness and electrical stimulation. J Biomed Mater Res A 2008, 86:253-260.
132. Cellot G., Cilia E., Cipollone S., et al. Carbon nanotubes might improve neuronal performance by favouring electrical shortcuts. Nat Nanotechnol 2009, 4:126-133.
133. Menard-Moyon C., Fabbro C., Prato M., Bianco A. One-pot triple functionalization of carbon nanotubes. Chem Eur J 2011, 17:3222-3227.
134. Bhirde A.A., Patel V., Gavard J., et al. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano 2009, 3:307-316.
135. Wang C.H., Huang Y.J., Chang C.W., Hsu W.M., Peng C.A. In vitro photothermal destruction of neuroblastoma cells using carbon nanotubes conjugated with GD2 monoclonal antibody. Nanotechnology 2009, 20:315101.
136. Welsher K., Liu Z., Sherlock S.P., et al. A route to brightly fluorescent carbon nanotubes for near-infrared imaging in mice. Nat Nanotechnol 2009, 4:773-780.
137. Liu Z., Davis C., Cai W., He L., Chen X., Dai H. Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc Natl Acad Sci USA 2008, 105:1410-1415.
138. Jacobs C.B., Peairs M.J., Venton B.J. Review: Carbon nanotube based electrochemical sensors for biomolecules. Anal Chim Acta 2010, 662:105-127.
139. Kostarelos K., Bianco A., Prato M. Promises, facts and challenges for carbon nanotubes in imaging and therapeutics. Nat Nanotechnol 2009, 4:627-633.
140. Singh R., Pantarotto D., Lacerda L., et al. Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. Proc Natl Acad Sci USA 2006, 103:3357-3362.
141. Gaillard C., Duval M., Dumortier H., Bianco A. Carbon nanotube-coupled cell adhesion peptides are non-immunogenic: A promising step toward new biomedical devices. J Pept Sci 2011, 17:139-142.